Search

Your search keyword '"Dhawan, Vijay"' showing total 43 results
Start Over Author "Dhawan, Vijay" Publication Year Range Last 10 years
43 results on '"Dhawan, Vijay"'

4. Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder

Author

Eidelberg, David, primary, Tang, Chris, additional, Nakano, Yoshikazu, additional, Vo, An, additional, Nguyen, Nha, additional, Schindlbeck, Katharina, additional, Poston, Kathleen, additional, Gagnon, Jean-François, additional, Postuma, Ronald, additional, Niethammer, Martin, additional, Ma, Yilong, additional, Peng, Shichun, additional, and Dhawan, Vijay, additional

Published
2024
Full Text
View/download PDF

5. Deep brain stimulation of the subthalamic nucleus for Parkinson’s disease: A network imaging marker of the treatment response

Author

Eidelberg, David, primary, Unadkat, Prashin, additional, Dhawan, Vijay, additional, Tang, Chris, additional, Ma, Yilong, additional, Peng, Shichun, additional, Vo, An, additional, Nguyen, Nha, additional, Niethammer, Martin, additional, Caminiti, Silvia Paola, additional, Perani, Daniela, additional, Ramdhani, Ritesh, additional, and Fenoy, Albert, additional

Published
2024
Full Text
View/download PDF

28. Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia

Author

Jourdain, Vincent A., primary, Schindlbeck, Katharina A., additional, Tang, Chris C., additional, Niethammer, Martin, additional, Choi, Yoon Young, additional, Markowitz, Daniel, additional, Nazem, Amir, additional, Nardi, Dominic, additional, Carras, Nicholas, additional, Feigin, Andrew, additional, Ma, Yilong, additional, Peng, Shichun, additional, Dhawan, Vijay, additional, and Eidelberg, David, additional

Published
2017
Full Text
View/download PDF

34. GZ402668, a Next-Generation Anti-CD52 Antibody, Displays Decreased Proinflammatory Cytokine Release In Vitro (P3.068)

Author

Siders, William, primary, Wei, Ronnie, additional, Greene, Ben, additional, McVie-Wylie, Alison, additional, Bailey, Meredith, additional, Dhawan, Vijay, additional, Best, Annie, additional, Brondyk, William, additional, Havari, Evis, additional, Turner, Michael, additional, Roberts, Bruce, additional, Kaplan, Johanne, additional, and Sendak, Rebecca, additional

Published
2016
Full Text
View/download PDF

37. Characterization of a Next Generation Anti-CD52 Antibody (S20.006)

Author

Siders, William, primary, Greene, Ben, additional, McVie-Wylie, Alison, additional, Bailey, Meredith, additional, Dhawan, Vijay, additional, Boutin, Paula, additional, Best, Annie, additional, Lawendowski, Carla, additional, Turner, Michael, additional, Roberts, Bruce, additional, Kaplan, Johanne, additional, and Sendak, Rebecca, additional

Published
2015
Full Text
View/download PDF

41. Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder.

Author

Eidelberg D, Tang C, Nakano Y, Vo A, Nguyen N, Schindlbeck K, Poston K, Gagnon JF, Postuma R, Niethammer M, Ma Y, Peng S, and Dhawan V

Abstract

Isolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal syndrome for Parkinson's disease (PD) and related α -synucleinopathies. We conducted a longitudinal imaging study of network changes in iRBD and their relationship to phenoconversion. Expression levels for the PD-related motor and cognitive networks (PDRP and PDCP) were measured at baseline, 2 and 4 years, along with dopamine transporter (DAT) binding. PDRP and PDCP expression increased over time, with higher values in the former network. While abnormal functional connections were identified initially within the PDRP, others bridging the two networks appeared later. A model based on the rates of PDRP progression and putamen dopamine loss predicted phenoconversion within 1.2 years in individuals with iRBD. In aggregate, the data suggest that maladaptive reorganization of brain networks takes place in iRBD years before phenoconversion. Network expression and DAT binding measures can be used together to assess phenoconversion risk in these individuals., Competing Interests: Additional Declarations: There is NO Competing Interest.

Published
2024
Full Text
View/download PDF

42. Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: A network imaging marker of the treatment response.

Author

Unadkat P, Vo A, Ma Y, Peng S, Nguyen N, Niethammer M, Tang CC, Dhawan V, Ramdhani R, Fenoy A, Caminiti SP, Perani D, and Eidelberg D

Abstract

Subthalamic nucleus deep brain stimulation (STN-DBS) alleviates motor symptoms of Parkinson's disease (PD), thereby improving quality of life. However, quantitative brain markers to evaluate DBS responses and select suitable patients for surgery are lacking. Here, we used metabolic brain imaging to identify a reproducible STN-DBS network for which individual expression levels increased with stimulation in proportion to motor benefit. Of note, measurements of network expression from metabolic and BOLD imaging obtained preoperatively predicted motor outcomes determined after DBS surgery. Based on these findings, we computed network expression in 175 PD patients, with time from diagnosis ranging from 0 to 21 years, and used the resulting data to predict the outcome of a potential STN-DBS procedure. While minimal benefit was predicted for patients with early disease, the proportion of potential responders increased after 4 years. Clinically meaningful improvement with stimulation was predicted in 18.9 - 27.3% of patients depending on disease duration.

Published
2024
Full Text
View/download PDF

43. Dynamic 18 F-FPCIT PET: Quantification of Parkinson's disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session.

Author

Peng S, Tang C, Schindlbeck K, Rydzinski Y, Dhawan V, Spetsieris PG, Ma Y, and Eidelberg D

Abstract

Previous multi-center imaging studies with 18 F-FDG PET have established the presence of Parkinson's disease motor- and cognition-related metabolic patterns termed PDRP and PDCP in patients with this disorder. Given that in PD cerebral perfusion and glucose metabolism are typically coupled in the absence of medication, we determined whether subject expression of these disease networks can be quantified in early-phase images from dynamic 18 F-FPCIT PET scans acquired to assess striatal dopamine transporter (DAT) binding. Methods: We studied a cohort of early-stage PD patients and age-matched healthy control subjects who underwent 18 F-FPCIT at baseline; scans were repeated 4 years later in a smaller subset of patients. The early 18 F-FPCIT frames, which reflect cerebral perfusion, were used to compute PDRP and PDCP expression (subject scores) in each subject, and compared to analogous measures computed based on 18 F-FDG PET scan when additionally available. The late 18 F-FPCIT frames were used to measure caudate and putamen DAT binding in the same individuals. Results: PDRP subject scores from early-phase 18 F-FPCIT and 18 F-FDG scans were elevated and striatal DAT binding reduced in PD versus healthy subjects. The PDRP scores from 18 F-FPCIT correlated with clinical motor ratings, disease duration, and with corresponding measures from 18 F-FDG PET. In addition to correlating with disease duration and analogous 18 F-FDG PET values, PDCP scores correlated with DAT binding in the caudate/anterior putamen. PDRP and PDCP subject scores using either method rose over 4 years whereas striatal DAT binding declined over the same time period. Conclusion: Early-phase images obtained with 18 F-FPCIT PET can provide an alternative to 18 F-FDG PET for PD network quantification. This technique therefore allows PDRP/PDCP expression and caudate/putamen DAT binding to be evaluated with a single tracer in one scanning session., (Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results